INTRODUCTION
Neurofibromas are slow-growing, painless, benign nervesheath tumors. They occur most commonly in the dermis and subcutis, and are rarely found in the breast (1) . Breast neurofibromas may develop as a result of inherited autosomal dominant neurofibromatosis type 1 (NF1) or randomly at a later time due to genetic mutations (2) . They usually appear as well-circumscribed oval masses on both mammography and ultrasonography (US), and are usually located on the nipple-areolar area (2-4).
We report a case of neurofibroma secondary to NF1 in the retromammary space resulting from endometrial cancer, which was detected on positron emission tomography-computed tomography (PET-CT) after hysterectomy.
CASE REPORT
A 50-year-old woman presented with a breast mass that showed mildly increased 18-fluorodeoxyglucose (FDG) uptake on outside PET-CT after hysterectomy for endometrioid adenocarcinoma. She had no breast-related complaints or general symptoms.
On examination, she had a 3 × 2 cm firm mass in the right upper outer (RUO) breast. She had multiple skin nodules since childhood, and her daughter and mother also had similar lesions. Fig. 1) Neurofibromas of the breast are rare. They are commonly found as solitary lesions or parts of neurofibromatosis type 1 and are usually located on the nipple-areolar area. We describe a case of neurofibroma of the breast in the retromammary space, which was detected on positron emission tomography-computed tomography after hysterectomy due to endometrial cancer. Neurofibromas are considered to be benign tumors, but a In our case, a US image showed a well-circumscribed mass surrounded by extramammary fat in the retromammary area that widely abutted the pectoralis major muscle (Fig. 2A) . On mammography and PET-CT, it appeared in the retromammary space and was separated from glandular tissue, indicating an extramammary location (Figs. 1, 2B ). The lesion was first detected on post-operative PET-CT with mild FDG uptake. The patient had undergone a hysterectomy because of endometrioid carcinoma. Metastasis was a possible diagnosis, but most metastases of the breast are located in the parenchyma and superficially, in the fat-parenchymal interface (8). As described above, the risk of breast cancer in patients with NF1 is higher than that of the normal population (6) . However, a breast cancer diagnosis was excluded because of the extramammary location of the lesion.
Mammography (
The patient's history of NF1 and the extramammary location of the lesion were clues that led to a diagnosis of neurofibroma.
MPNST, a leading cause of death in NF1 patients, cannot be reliably distinguished from neurofibroma by US (9) . Therefore, if a lesion shows increased FDG uptake on PET-CT, MPNST
should be considered and a histological diagnosis is necessary.
Neurofibromas are white-gray, soft, and well circumscribed but not encapsulated (10) . They vary in shape and size, mostly measuring between 1 and 2 cm (4, 5). Neurofibromas are formed by a combined proliferation of all the elements of a peripheral nerve, with Schwann cells being the most predominant entities (5) . Most are immunoreactive to S100 protein and, in keeping with their benign behavior, lack significant mitotic activity and necrosis (10) . Schwannomas may be differentiated from neurofibromas by the presence of Verocay bodies, Antoni A and B areas, and a more diffuse and uniform S100 staining pattern (5, 10) . These features were all absent in our case.
In conclusion, neurofibroma of the breast is rare but should be included in the differential diagnosis of breast lesion in NF1
patients. Though it can have nonspecific imaging features, its extramammary location on mammography and US is useful in distinguishing it from parenchymal lesions. 
